Febuxostat
- Generic Name
- Febuxostat
- Brand Names
- Adenuric, Uloric, Febuxostat Viatris (previously Febuxostat Mylan), Febuxostat Krka
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16N2O3S
- CAS Number
- 144060-53-7
- Unique Ingredient Identifier
- 101V0R1N2E
- Background
Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate r...
- Indication
Febuxostat is indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. It is not recommended for the treatment of asymptomatic hyperuricemia or secondary hyperuricem...
- Associated Conditions
- Chronic, symptomatic Hyperuricemia
- Associated Therapies
- -
Study on the Efficacy and Safety of Thermotherapy in the Treatment of Refractory Gout
- Conditions
- Interventions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 128
- Registration Number
- NCT06653686
The Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT06622603
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine
- Conditions
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 46
- Registration Number
- NCT06525974
A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06501534
- Locations
- 🇨🇳
Shanghai Fudan University HuaShan Hospital, Shanghai, Shanghai, China
A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
- Conditions
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 451
- Registration Number
- NCT05007392
- Locations
- 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳Yanbian University Hospital, Yanji, Jilin, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
Hyperuricemia and Diabetic Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 200
- Registration Number
- NCT04799925
Role of Uralyt-U in Patients With Hyperuricemia
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Ai Peng
- Target Recruit Count
- 102
- Registration Number
- NCT04352153
- Locations
- 🇨🇳
Department of Nephrolgoy, Shanghai 10th People's Hospital, Shanghai, Shanghai, China
Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2019-08-30
- Target Recruit Count
- 72
- Registration Number
- NCT04069325
- Locations
- 🇨🇳
Guang'anmen Hospital, Beijing, Beijing, China
Bioequivalence Study of Two Formulations of Febuxostat 120 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 50
- Registration Number
- NCT03918551
- Locations
- 🇨🇦
Altasciences Company Inc., Montréal, Quebec, Canada
Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
- Target Recruit Count
- 558
- Registration Number
- NCT03767322
- Locations
- 🇲🇽
Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, México City, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.